Dasatinib Down-regulates the Expression of PD-1 and Enhances Killing pH + Leukemia Stem Cells

Phase I/Ib Multiple Ascending Dose Study in China

NCT03523390 ·Status: COMPLETED ·Phase: PHASE1

Study of CM518D1 in Patients With Advanced Solid Tumors

NCT07019779 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

NCT05923515 ·Status: UNKNOWN ·Phase: PHASE1

A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer

NCT03789604 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC

NCT05724355 ·Status: UNKNOWN ·Phase: PHASE2

Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients

NCT04421352 ·Status: COMPLETED ·Phase: PHASE1

D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)

NCT02651441 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Checkpoint Inhibitors in Patients With Solid Tumors: a Retrospective Real-world Study

NCT05719324 ·Status: UNKNOWN

First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors

NCT07265622 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma

NCT07062484 ·Status: NOT_YET_RECRUITING ·Phase: NA

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

NCT03852823 ·Status: UNKNOWN ·Phase: PHASE1

Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

NCT03919552 ·Status: RECRUITING ·Phase: PHASE3

Study to Evaluate the Mass Balance and Biotransformation of [14C]-Fluzoparib in Chinese Patients With Solid Tumor

NCT04013048 ·Status: COMPLETED ·Phase: PHASE1

A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.

NCT05877924 ·Status: RECRUITING ·Phase: PHASE1

Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors

NCT07292038 ·Status: RECRUITING ·Phase: PHASE1

Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

NCT06490081 ·Status: RECRUITING ·Phase: PHASE2

PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC

NCT07235319 ·Status: RECRUITING ·Phase: PHASE3

Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China

NCT01863485 ·Status: COMPLETED ·Phase: PHASE1

Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis

NCT04171986 ·Status: UNKNOWN ·Phase: NA

Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLC

NCT04153097 ·Status: UNKNOWN

Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma

NCT04453826 ·Status: RECRUITING ·Phase: PHASE3

Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma

NCT03930498 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Sintilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer

NCT05312840 ·Status: COMPLETED ·Phase: PHASE4

A Study of DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors

NCT06873542 ·Status: COMPLETED ·Phase: PHASE1

A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors

NCT05773937 ·Status: RECRUITING ·Phase: PHASE1